Patients Ages 3–17 Sought for Large-Scale Trial Testing CBD Gel Zygel

Patients Ages 3–17 Sought for Large-Scale Trial Testing CBD Gel Zygel

309318

Patients Ages 3–17 Sought for Large-Scale Trial Testing CBD Gel Zygel

Zynerba Pharmaceuticals is recruiting children and adolescents with fragile X syndrome for a large-scale clinical trial testing the safety and efficacy of the cannabidiol (CBD) gel Zygel for treating behavioral problems. The Phase 3 trial, called RECONNECT, is enrolling participants ages 3—17 at 26 sites across the U.S., Australia, the U.K., and Ireland. More information on contacts and locations can be found here. “If successful, we believe the study could serve as the basis for Zygel approval…

You must be logged in to read/download the full post.